The novel angiotensin II type 2 receptor agonist buloxibutid improves lung function in IPF compared to real-world external IPF control arms - Amsterdam 2025

Emerging clinical trials in pulmonary fibrosis

Chair(s): Nazia Chaudhuri, Wim A. Wuyts

Session type: Oral presentation

The novel angiotensin II type 2 receptor agonist buloxibutid improves lung function in IPF compared to real-world external IPF control arms

Toby M Maher

EVENTS HOME

Previous presentation

Next presentation

Session content

The novel angiotensin II type 2 receptor agonist buloxibutid improves lung function in IPF compared to real-world external IPF control arms

Toby M Maher

Replay

Abstract

Slides

Phase 2a signal searching study with zelasudil in idiopathic pulmonary fibrosis (IPF)

Toby M Maher

Replay

Poster

Abstract

Slides

Rentosertib, a generative AI-discovered TNIK inhibitor improves lung function in IPF patients

Carol Satler

Replay

Poster

Abstract

Slides

Initiation of supplemental oxygen in the FIBRONEER-IPF trial of nerandomilast in patients with idiopathic pulmonary fibrosis

Marlies S. Wijsenbeek

Replay

Poster

Abstract

Slides

Effect of nerandomilast in subgroups of patients with idiopathic pulmonary fibrosis (IPF) in the FIBRONEER-IPF trial

Claudia Valenzuela

Replay

Poster

Abstract

Slides

TETON phase 3 clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis

Steven D Nathan

Replay

Poster

Abstract

Slides

TETON-PPF clinical trial of inhaled treprostinil for the treatment of progressive pulmonary fibrosis

Steven D Nathan

Replay

Poster

Abstract

Slides

The COCOS-IPF Core Outcome Set for progressive pulmonary fibrosis

Sofie Breuls

Replay

Poster

Abstract

Slides

IPF COMFORT Study: A randomised, controlled trial evaluating the safety and efficacy of orvepitant as a treatment for chronic cough in IPF

Surinder S. Birring

Replay

Poster

Abstract

Slides

Discussion and Q&A

Replay

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}